

**IB. AMENDMENTS TO THE CLAIMS**

Cancel claims 1-33 without prejudice to renewal.

Please enter new claims 34-41, as shown below.

1.-33. (Canceled)

34. (New) An isolated human plasma hyaluronidase polypeptide, wherein said polypeptide is glycosylated.

35. (New) The polypeptide of claim 34, wherein said glycosylation is sensitive to N-glycosidase-F treatment.

36. (New) The polypeptide of claim 34, wherein said glycosylation comprises a mannose residue.

37. (New) The polypeptide of claim 34, wherein said polypeptide further comprises a fatty acid modification.

38. (New) The polypeptide of claim 37, wherein said fatty acid modification is resistant to phospholipase-C, phospholipase-D, and N-glycosidase-F.

39. (New) The polypeptide of claim 34, wherein said polypeptide is enzymatically active.

40. (New) The polypeptide of claim 39, wherein said polypeptide exhibits a specific activity of at least about  $6 \times 10^5$  relative turbidity reducing units per mg protein.

41. (New) The polypeptide of claim 34, wherein said polypeptide has a relative molecular mass of about 57 kDa as determined by sodium dodecyl sulfate polyacrylamide gel electrophoresis.